R. Yamanaka and A. Hayano, Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review, World Neurosurg, 2017.

S. Pinson, A. Créange, S. Barbarot, J. F. Stalder, Y. Chaix et al.,

, Ann Dermatol Venereol, vol.128, pp.567-75, 2001.

T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller, and J. M. Friedman, Association between benign and malignant peripheral nerve sheath tumors in NF1, Neurology, vol.65, pp.205-216, 2005.

E. Sbidian, S. Bastuji-garin, L. Valeyrie-allanore, S. Ferkal, and J. P. Lefaucheur,

A. Drouet, At-risk phenotype of neurofibromatose-1 patients: a multicentre casecontrol study, Orphanet J Rare Dis, vol.6, p.51, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00613196

V. Mautner, F. A. Asuagbor, E. Dombi, C. Fünsterer, L. Kluwe et al., Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1, Neuro Oncol, vol.10, pp.593-601, 2008.

D. Evans, H. Salvador, V. Y. Chang, A. Erez, S. D. Voss et al., Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1, Clin Cancer Res, vol.23, pp.46-53, 2017.

J. Salamon, V. F. Mautner, G. Adam, and T. Derlin, Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors, Rofo, vol.187, pp.1084-92, 2015.

A. Van-der-gucht, O. Zehou, S. Djelbani-ahmed, L. Valeyrie-allanore, N. Ortonne et al., Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1, PLoS ONE, vol.11, p.151809, 2016.

S. Sharif, A. Moran, S. M. Huson, R. Iddenden, A. Shenton et al.,

S. A. Madanikia, A. Bergner, X. Ye, and J. O. Blakeley, Increased risk of breast cancer in women with NF1, Am J Med Genet A, vol.158, pp.3056-60, 2012.

T. De-raedt, H. Brems, P. Wolkenstein, D. Vidaud, S. Pilotti et al.,

, Elevated Risk for MPNST in NF1 Microdeletion Patients, Am J Hum Genet, vol.72, pp.1288-92, 2003.

V. Mautner, L. Kluwe, R. E. Friedrich, A. C. Roehl, S. Bammert et al.,

, Mb type-1 NF1 deletions, J Med Genet, vol.47, pp.623-653, 2010.

D. Evans, M. E. Baser, J. Mcgaughran, S. Sharif, E. Howard et al.,

D. H. Gutmann, D. L. Wood, and F. S. Collins, Identification of the neurofibromatosis type 1 gene product, Proc Natl Acad Sci, vol.88, issue.21, pp.9658-62, 1991.

S. A. Rasmussen and J. M. Friedman, NF1 gene and neurofibromatosis 1, Am J Epidemiol. 1 janv, vol.151, issue.1, pp.33-40, 2000.

M. Snajderova, V. M. Riccardi, B. Petrak, D. Zemkova, J. Zapletalova et al., The importance of advanced parental age in the origin of neurofibromatosis type 1, Am J Med Genet A. mars, vol.158, issue.3, pp.519-542, 2012.

K. Mckeever, C. W. Shepherd, H. Crawford, and P. J. Morrison, An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age, Ulster Med J. sept, vol.77, issue.3, pp.160-163, 2008.

M. Zöller, B. Rembeck, H. O. Akesson, and L. Angervall, Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Acta Derm Venereol. mars, vol.75, issue.2, pp.136-176, 1995.

S. M. Huson, D. A. Compston, P. Clark, and P. S. Harper, A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity, J Med Genet, vol.26, issue.11, pp.704-715, 1989.

A. Bernards, Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs, Biochim Biophys Acta. 28 juill, vol.1242, issue.1, pp.43-59, 1995.

L. M. Messiaen, T. Callens, G. Mortier, D. Beysen, I. Vandenbroucke et al., Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects

, Hum Mutat, vol.15, issue.6, pp.541-55, 2000.

J. E. Declue, B. D. Cohen, and D. R. Lowy, Identification and characterization of the neurofibromatosis type 1 protein product, Proc Natl Acad Sci, vol.88, issue.22, pp.9914-9922, 1991.

T. N. Basu, D. H. Gutmann, J. A. Fletcher, T. W. Glover, F. S. Collins et al., Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients, Nature. 23 avr, vol.356, issue.6371, pp.713-718, 1992.

B. Dasgupta, Y. Yi, D. Y. Chen, J. D. Weber, and D. H. Gutmann, Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors, Cancer Res. 1 avr, vol.65, issue.7, pp.2755-60, 2005.

D. H. Gutmann, R. E. Ferner, R. H. Listernick, B. R. Korf, P. L. Wolters et al., Neurofibromatosis type 1. Nat Rev Dis Primers, 23 févr, vol.3, p.17004, 2017.

M. Upadhyaya, S. M. Huson, M. Davies, N. Thomas, N. Chuzhanova et al., An Absence of Cutaneous Neurofibromas Associated with a 3-bp Inframe Deletion in Exon 17 of the NF1 Gene (c.2970-2972 delAAT): Evidence of a Clinically Significant NF1 Genotype-Phenotype Correlation, Am J Hum Genet. janv, vol.80, issue.1, pp.140-51, 2007.

K. Rojnueangnit, J. Xie, A. Gomes, A. Sharp, T. Callens et al., High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation, Hum Mutat, vol.36, issue.11, pp.1052-63, 2015.

H. Kehrer-sawatzki, V. Mautner, and D. N. Cooper, Emerging genotype-phenotype relationships in patients with large NF1 deletions, Hum Genet, vol.136, issue.4, pp.349-76, 2017.

D. F. Easton, M. A. Ponder, S. M. Huson, and B. A. Ponder, An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes, Am J Hum Genet. août, vol.53, issue.2, pp.305-318, 1993.

E. Pasmant, A. Sabbagh, J. Masliah-planchon, N. Ortonne, I. Laurendeau et al., Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1, J Natl Cancer Inst, vol.103, issue.22, pp.1713-1735, 2011.

, Conference statement. National Institutes of Health Consensus Development Conference, Neurofibromatosis, vol.45, issue.5, pp.575-583, 1988.

S. Pinson, A. Créange, S. Barbarot, J. F. Stalder, Y. Chaix et al.,

, Ann Dermatol Venereol. avr, vol.128, issue.4, pp.567-75, 2001.

D. Schepper, S. Maertens, O. Callens, T. Naeyaert, J. Lambert et al., Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes, J Invest Dermatol. avr, vol.128, issue.4, pp.1050-1053, 2008.

V. Riccardi, Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 2nd, 1992.

H. Li, X. Zhang, L. Fishbein, F. Kweh, M. C. Thompson et al., Analysis of steroid hormone effects on xenografted human NF1 tumor Schwann cells

, Cancer Biol Ther, vol.15, issue.8, pp.758-64, 2010.

Z. Chen, C. Liu, A. J. Patel, C. Liao, Y. Wang et al., Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. Cancer Cell, vol.26, pp.695-706, 2014.

J. M. Friedman and P. H. Birch, Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients, Am J Med Genet. 16 mai, vol.70, issue.2, pp.138-181, 1997.

G. C. Daginakatte and D. H. Gutmann, Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth, Hum Mol Genet. 1 mai, vol.16, issue.9, pp.1098-112, 2007.

R. Sharma, X. Wu, S. D. Rhodes, S. Chen, Y. He et al.,

, Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromindeficient mice, Hum Mol Genet. 1 déc, vol.22, issue.23, pp.4818-4846, 2013.

K. S. Nunley, F. Gao, A. C. Albers, S. J. Bayliss, and D. H. Gutmann, Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1, Arch Dermatol. août, vol.145, issue.8, pp.883-890, 2009.

D. G. Evans, N. Bowers, E. Burkitt-wright, E. Miles, S. Garg et al., Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1

, Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only, EBioMedicine. 13 avr, vol.7, pp.212-232, 2016.

K. Debella, K. Poskitt, J. Szudek, and J. M. Friedman, Use of « unidentified bright objects » on MRI for diagnosis of neurofibromatosis 1 in children, Neurology. 25 avr, vol.54, issue.8, pp.1646-51, 2000.

N. J. Ullrich, A. I. Raja, M. B. Irons, M. W. Kieran, and L. Goumnerova, Brainstem lesions in neurofibromatosis type 1. Neurosurgery, vol.61, pp.762-766, 2007.

M. Han and E. Criado, Renal artery stenosis and aneurysms associated with neurofibromatosis, J Vasc Surg. mars, vol.41, issue.3, pp.539-582, 2005.

S. Cambiaghi, L. Restano, and R. Caputo, Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies, Pediatr Dermatol. avr, vol.21, issue.2, pp.97-101, 2004.

E. Cham, D. Siegel, and B. S. Ruben, Cutaneous xanthogranulomas, hepatosplenomegaly, anemia, and thrombocytopenia as presenting signs of juvenile myelomonocytic leukemia, Am J Clin Dermatol, vol.11, issue.1, pp.67-71, 2010.

E. Heervä, A. Koffert, E. Jokinen, T. Kuorilehto, S. Peltonen et al., A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age, J Bone Miner Res, vol.27, issue.11, pp.2333-2340, 2012.

D. Evans, M. E. Baser, J. Mcgaughran, S. Sharif, E. Howard et al., Malignant peripheral nerve sheath tumours in neurofibromatosis 1, J Med Genet. mai, vol.39, issue.5, pp.311-315, 2002.

A. Drouet, P. Wolkenstein, J. Lefaucheur, S. Pinson, P. Combemale et al., Neurofibromatosis 1-associated neuropathies: a reappraisal, Brain. sept, vol.127, pp.1993-2009, 2004.

R. E. Ferner, .. C. Hughes-r-a, S. M. Hall, M. Upadhyaya, and M. R. Johnson, Neurofibromatous neuropathy in neurofibromatosis 1 (NF1), J Med Genet, vol.41, issue.11, pp.837-878, 2004.

P. F. Doorn, W. M. Molenaar, J. Buter, and H. J. Hoekstra, Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis, Eur J Surg Oncol. févr, vol.21, issue.1, pp.78-82, 1995.

M. Poyhonen, S. Niemela, and R. Herva, Risk of malignancy and death in neurofibromatosis, Arch Pathol Lab Med. févr, vol.121, issue.2, pp.139-182, 1997.

T. De-raedt, H. Brems, P. Wolkenstein, D. Vidaud, S. Pilotti et al.,

, Elevated Risk for MPNST in NF1 Microdeletion Patients, Am J Hum Genet. mai, vol.72, issue.5, pp.1288-92, 2003.

D. E. Porter, V. Prasad, L. Foster, G. F. Dall, R. Birch et al., Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours, Sarcoma, p.756395, 2009.

J. M. Pappachan, D. Raskauskiene, R. Sriraman, M. Edavalath, and F. W. Hanna, Diagnosis and management of pheochromocytoma: a practical guide to clinicians, Curr Hypertens Rep. juill, vol.16, issue.7, p.442, 2014.

H. Joensuu, P. Hohenberger, and C. L. Corless, Gastrointestinal stromal tumour
URL : https://hal.archives-ouvertes.fr/hal-02301886

, Lancet. 14 sept, vol.382, issue.9896, pp.973-83, 2013.

P. Wolkenstein, B. Frèche, J. Zeller, and J. Revuz, Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients, Arch Dermatol, vol.132, issue.11, pp.1333-1339, 1996.

S. M. Huson, What level of care for the neurofibromatoses? The Lancet. 3 avr, vol.353, pp.1114-1120, 1999.

R. E. Ferner, S. M. Huson, N. Thomas, C. Moss, H. Willshaw et al., Guidelines for the diagnosis and management of individuals with neurofibromatosis 1, J Med Genet. févr, vol.44, issue.2, pp.81-89, 2007.

D. Evans, H. Salvador, V. Y. Chang, A. Erez, S. D. Voss et al., Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1, Clin Cancer Res. 15 juin, vol.23, issue.12, pp.46-53, 2017.

E. Uusitalo, M. Rantanen, R. A. Kallionpää, M. Pöyhönen, J. Leppävirta et al., Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1, J Clin Oncol. 10 juin, vol.34, issue.17, pp.1978-86, 2016.

S. Sharif, A. Moran, S. M. Huson, R. Iddenden, A. Shenton et al., Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening, J Med Genet. août, vol.44, issue.8, pp.481-485, 2007.

V. Mautner, F. A. Asuagbor, E. Dombi, C. Fünsterer, L. Kluwe et al., Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1, Neuro Oncol. août, vol.10, issue.4, pp.593-601, 2008.

T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller, and J. M. Friedman, Association between benign and malignant peripheral nerve sheath tumors in NF1, Neurology. 26 juill, vol.65, issue.2, pp.205-216, 2005.

R. Listernick, R. E. Ferner, G. T. Liu, and D. H. Gutmann, Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations, Ann Neurol. mars, vol.61, issue.3, pp.189-98, 2007.

M. H. Cnossen, E. N. Stam, L. C. Cooiman, H. J. Simonsz, H. Stroink et al., Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics, vol.100, pp.667-70, 1997.

S. Singhal, J. Birch, B. Kerr, L. Lashford, and D. Evans, Neurofibromatosis type 1 and sporadic optic gliomas, Arch Dis Child. juill, vol.87, issue.1, pp.65-70, 2002.

C. Cassiman, E. Legius, W. Spileers, and I. Casteels, Ophthalmological assessment of children with neurofibromatosis type 1, Eur J Pediatr. oct, vol.172, issue.10, pp.1327-1360, 2013.

R. Listernick, C. Darling, M. Greenwald, L. Strauss, and J. Charrow, Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history, J Pediatr. nov, vol.127, issue.5, pp.718-740, 1995.

R. Listernick, J. Charrow, and M. Greenwald, Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results, J Pediatr, vol.121, issue.4, pp.584-591, 1992.

A. J. Sievert and M. J. Fisher, Pediatric low-grade gliomas, J Child Neurol, vol.24, issue.11, pp.1397-408, 2009.

R. A. Avery, M. J. Fisher, and G. T. Liu, Optic pathway gliomas, J Neuroophthalmol. sept, vol.31, issue.3, pp.269-78, 2011.

M. J. Fisher, M. Loguidice, D. H. Gutmann, R. Listernick, R. E. Ferner et al., Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis, Neuro-oncology. juin, vol.14, issue.6, pp.790-797, 2012.

A. King, R. Listernick, J. Charrow, L. Piersall, and D. H. Gutmann, Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome, Am J Med Genet A, vol.122, issue.2, pp.95-104, 2003.

S. Thiagalingam, M. Flaherty, F. Billson, and K. North, Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients, Ophthalmology. mars, vol.111, issue.3, pp.568-77, 2004.

D. Blank, P. Fisher, M. J. Liu, G. T. Gutmann, D. H. Listernick et al., Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision, J Neuroophthalmol. sept, vol.37, issue.1, pp.23-32, 2017.

V. Mautner, L. Kluwe, R. E. Friedrich, A. C. Roehl, S. Bammert et al., Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions, J Med Genet. sept, vol.47, issue.9, pp.623-653, 2010.

W. Lee, S. Teckie, T. Wiesner, L. Ran, P. Granada et al., PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors, Nat Genet, vol.46, issue.11, pp.1227-1259, 2014.

D. W. Bell, N. Sikdar, K. Lee, J. C. Price, R. Chatterjee et al., Predisposition to Cancer Caused by Genetic and Functional Defects of

M. Atad5, PLOS Genetics. août, vol.7, issue.8, p.1002245, 2011.

A. Sedani, D. N. Cooper, and M. Upadhyaya, An emerging role for microRNAs in NF1 tumorigenesis, Hum Genomics, vol.6, issue.1, p.23, 2012.